Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.
Autor: | Nasiri A; Hematology, King Faisal Specialist Hospital & Research Centre, Riyadh, SAU., Lami A; Internal Medicine, Security Forces Hospital, Riydah, SAU., Alhumaidi A; Internal Medicine, Security Forces Hospital, Riyadh, SAU., Madkhali A; Internal Medicine, Security Forces Hospital, Riyadh, SAU., Althaqib A; Internal Medicine, Security Forces Hospital, Riyadh, SAU., Aljarwan N; Internal Medicine, Security Forces Hospital, Riyadh, SAU., Alkharras R; Internal Medicine, Security Forces Hospital, Riyadh, SAU. |
---|---|
Jazyk: | angličtina |
Zdroj: | Cureus [Cureus] 2023 Apr 01; Vol. 15 (4), pp. e37016. Date of Electronic Publication: 2023 Apr 01 (Print Publication: 2023). |
DOI: | 10.7759/cureus.37016 |
Abstrakt: | Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an uncommon hematological tumor originating from the precursor of plasmacytoid dendritic cells (pDCs) with a persistent and progressive course of illness. Despite being an aggressive disease BPDCN has an initial indolent course manifested as skin lesions. Alongside or following the skin lesion, the extra-cutaneous manifestation develops and includes lymphadenopathy, splenomegaly, and hepatomegaly. The BPDCN diagnosis is mainly based on the immunophenotype. Herein, we report the case of a 72-year-old male patient who presented with a history of left anterior chest wall painless skin lesions. Histology of skin biopsy of the left chest skin lesion showed diffuse dermal infiltration by monomorphic medium-sized blastic cells positive for cluster of differentiation (CD)4, CD45, CD7, CD56, CD43, CD123, T-cell leukemia-1 (TCL1), and B-cell leukemia/lymphoma 2 protein (BCL2). Given the rarity of the disease, standard chemotherapy regimens used in treating different leukemias and lymphomas have been adapted to treat BPDCN. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Nasiri et al.) |
Databáze: | MEDLINE |
Externí odkaz: |